A narrative review examines how generative AI tools such as large language models and vision-language models could assist precision oncology by interpreting genomic data, matching patients to clinical ...

This March, join the Alliance for Clinical Trials in Oncology (Alliance) and the Alliance Foundation Trials (AFT) in spotlighting colorectal cancer, the second leading cause of cancer-related death in ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), ...

Jody Agena, PharmD, MBA, director of pharmacy operations, Virginia Cancer Specialists, discusses the various responsibilities of the pharmacist within community oncology settings. The clinical ...

As immunotherapy reshaped cancer care, geriatric oncology shifted toward personalized, geriatric assessment-guided treatment that prioritizes function, safety, and what matters most to older adults.

Nanomedicine is rapidly transforming the landscape of cancer treatment through the development of advanced drug-delivery carriers. Despite notable progress ...

Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma In this phase II, open-label study, patients with recurrent, ...

As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...

COA emphasizes importance of supporting digital transformation in community settings to achieve goals for quality, ...

Oncology rehabilitation and exercise (ORE) exist along a continuum of care, providing essential services for patients with cancer to improve health outcomes. Although oncology rehabilitation, ...

Investigators assessed characteristics that may predict patient satisfaction across various domains following Mohs micrographic surgery.

Executives from CG Oncology (NASDAQ:CGON) outlined clinical results, ongoing trials, and launch preparations for its investigational intravesical therapy cretostimogene (referred to as “Credo”) during ...